Raltegravir treatment response in an HIV-2 infected patient: a case report.
about
HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Raltegravir: The evidence of its therapeutic value in HIV-1 infection.Polymorphisms of HIV-2 integrase and selection of resistance to raltegravirThree main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimensAntiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsHot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravirCharacteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study.Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapyIn vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.Antiretroviral drug resistance in human immunodeficiency virus type 2.Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance
P2860
Q33963958-5848E96D-64E9-47CA-B147-3454D88AD433Q33973930-E0C6FDFA-51BE-4F8A-85AD-91388DD32977Q34426605-BA3F0E23-085E-4C3F-A838-4D3412CA96BFQ34428902-9CE06D97-3A43-48C8-AC60-FB6F0F7B48BAQ34730950-5AF2A1D9-CCB6-4C0E-8DDA-4102C4DE764DQ34737268-6CE391BF-668E-4203-80ED-87D7DCAFAEE4Q34793224-2A51848D-4F10-49E5-83CD-B8CCF43E0B69Q35026582-7F1F51F7-D7CD-42AF-A45F-A16CF815D313Q35083423-56D8DE53-64E1-4915-901F-EC233D81DED0Q35134947-19FAB05F-99B4-4418-A605-3E22AAF539E3Q35206272-23B62C73-1E01-4300-83E0-0BB2EB1A71A8Q36290647-5B315C6B-471F-40DD-9066-7AD766E8D789Q36839676-08E445C1-47AE-43AF-B5D4-2964C708D5F9Q37405336-DF9F78FB-CC39-4F54-9F95-EAB4F45DB967Q37496287-CEADE092-9B8E-4E7D-8C70-1598B284AB2CQ37979697-226585B5-1DB0-4432-95FB-3E6EA0985211Q40883043-C5C74EAB-9EE7-4AA3-862A-626BBEC7DAD5Q48066731-F33D161A-2009-4572-A59C-877C9D8F5DFAQ52625498-E890929F-AD96-4B05-A3A2-D672841BD9A3Q58391480-7ADB84F4-0C03-45CA-82BC-96AE95D81839
P2860
Raltegravir treatment response in an HIV-2 infected patient: a case report.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Raltegravir treatment response in an HIV-2 infected patient: a case report.
@en
Raltegravir treatment response in an HIV-2 infected patient: a case report.
@nl
type
label
Raltegravir treatment response in an HIV-2 infected patient: a case report.
@en
Raltegravir treatment response in an HIV-2 infected patient: a case report.
@nl
prefLabel
Raltegravir treatment response in an HIV-2 infected patient: a case report.
@en
Raltegravir treatment response in an HIV-2 infected patient: a case report.
@nl
P2093
P1433
P1476
Raltegravir treatment response in an HIV-2 infected patient: a case report.
@en
P2093
Bridget Ferns
Erasmus Smit
Saleh El-Gadi
P304
P356
10.1097/QAD.0B013E3282F9B165
P407
P577
2008-05-01T00:00:00Z